Coherus BioSciences (CHRS) Reports Q3 EPS of $1.67

Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of $1.67, versus ($1.86) reported last year. Revenue for the quarter came in at $162.8 million, versus $7.2 million reported last year.

For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Twin Disc (TWIN) Tops Q4 EPS by 16c